COVID-19 Treatment Clinics

These clinics have been launched to help our patients access outpatient therapies such as monoclonal antibody treatment when available.

The Inova Extended COVID-19 Care Clinics are accepting referrals for patients from all Inova Emergency Rooms, Inova Urgent Care Centers, Inova Primary Care Offices, as well as community practices.

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. The monoclonal antibody treatments offered specifically target the spike protein.

Monoclonal antibodies can be delivered by both infusion or by subcutaneous injection. 

Patients who have symptomatic COVID, vaccinated or unvaccinated, are eligible if they have a positive test, have had symptom onset within the past 10 days, and also meet one of the following high risk criteria:

Patients 12 or older who weigh at least 40 kg who have the following risk factors:

• Older age (>=65)
• Obesity with a BMI of >=25 for adults or BMI >= 85th percentile for children age 12-17
• Pregnancy
• Chronic kidney disease
• Diabetes
• Immunosuppressive disease or on immunosuppressive treatment
• Cardiovascular disease, including congenital heart disease or hypertension
• Chronic lung disease, including, but not limited to, asthma and COPD
• Sickle cell disease
• Neurodevelopmental disorders (i.e. cerebral palsy) or other conditions that confer medical complexity, such as genetic or metabolic syndromes and severe congenital abnormalities
• Having a medical related technological dependence, i.e. tracheostomy, gastrostomy, or positive pressure ventilation
• Presence of other medical or non-medical risk factors, including race or ethnicity, that may also confer high risk for severe disease.

Patients who have been exposed to COVID who are not expected to mount an adequate response to vaccination due to an immunosuppressive illness or medication as well as patients who are not fully vaccinated who also have one of the risk factors above are also eligible for treatment.

Providers:

• Complete this form to refer a symptomatic patient
• Complete this form to refer a post exposure prophylaxis patient

Patients:

To be referred, please contact your primary care provider.

If you do not have a primary care provider, complete one of the following self-referral forms and you will be scheduled for a telemedicine appointment with an Inova Primary Care Provider to see if you qualify for the monoclonal infusion treatment.

• Complete this form if you are experiencing symptoms of COVID-19 (symptomatic patients)
• Complete this form if you have been exposted to COVID-19 (post exposure prophylaxis)

Once you have completed the online form, a scheduler will contact you. You can also call 571-472-4502 to schedule your telemedicine assessment appointment.

The monoclonal antibody treatment is currently available by the FDA through Emergency Use Authorization (EUA).

An Emergency Use Authorization (EUA) is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies, such as the current COVID-19 pandemic.

The COVID-19 treatment has been proven to reduce hospital admissions. The most common side effect shown in studies has been nausea. This medication has been very well tolerated. Nevertheless, Inova providers will be closely monitoring you for 1 hour after treatment to ensure your safety.

There have not been any studies on pregnant patients. Given the low risk associated with this medication, pregnant patients can receive the treatment if requested.

The cost of any telemedicine visits or infusion fee are covered by Medicare, Medicaid, and commercial insurance. Co-pays may apply. The infusion and telemedicine visits are available to the uninsured who can apply for financial assistance.

Inova is not charging for the COVID-19 treatment, but will charge for administering the medication. Charges will vary depending on your coverage.

Uninsured patients can apply for financial assistance. Financial assistance coverage will depend on qualifications.